Stoke Therapeutics, Inc. (STOK) Misses Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts STOK Hot Sheet
Join SI Premium – FREE
Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q3 EPS of ($0.65), $0.07 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $10.63 million versus the consensus estimate of $6.06 million.
For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbnb (ABNB) call put ratio 1 call to 1.3 puts into quarter results
- Sunrun (RUN) call put ratio 7 calls to 1 put with a focus on January 17 calls as share price up 7.8%
- Lyft (LYFT) March 13 puts active into quarter results
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
